What's new

Human medicines European public assessment report (EPAR): Namuscla, mexiletine hcl, Date of authorisation: 18/12/2018, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Namuscla, mexiletine hcl, Date of authorisation: 18/12/2018, Revision: 6, Status: Authorised

Mar 19, 2025 - 17:03
 0
Human medicines European public assessment report (EPAR): Namuscla, mexiletine hcl, Date of authorisation: 18/12/2018, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Namuscla, mexiletine hcl, Date of authorisation: 18/12/2018, Revision: 6, Status: Authorised
Read More

Tags:

Previous Article

Immunovant claims study success for immune disease drug but holds off on submission

Next Article

Today’s D Brief: Trump takes Putin’s offer; ‘Dogfighting in space’; DOD’s person...

Related Posts

Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0

Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 5, 2025  0